Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04439344 · FLOW

Participant flow

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) · Source last updated 2026-05-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Binimetinib: Given PO
    id
    FG000
    title
    Treatment (Binimetinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Never started threapy
    2. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Ineligible
    3. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    5. reasons
      1. group Id
        FG000
        num Subjects
        29
      type
      Disease progression
    6. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Withdrawal by Subject
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Alternative therapy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        50
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        47
      type
      Eligible
    4. achievements
      1. group Id
        FG000
        num Subjects
        0
      comment
      Treatment continued until disease progression or intolerability.
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol Z1A, patients had to have a tumor harboring a codon 12, 13, or 61 NRAS-mutation.
recruitment Details
Subprotocol Z1A was activated on May 31, 2016. A total of 114 patients were assigned to this arm after screening, all from screening cohort. Of the 114 patients, 53 patients were enrolled to arm Z1A in the period from May 31, 2016 and June 7, 2018.
Complete source fields
groups
  1. description
    Patients receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Binimetinib: Given PO
    id
    FG000
    title
    Treatment (Binimetinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Never started threapy
    2. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Ineligible
    3. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    5. reasons
      1. group Id
        FG000
        num Subjects
        29
      type
      Disease progression
    6. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Withdrawal by Subject
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Alternative therapy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        50
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        47
      type
      Eligible
    4. achievements
      1. group Id
        FG000
        num Subjects
        0
      comment
      Treatment continued until disease progression or intolerability.
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol Z1A, patients had to have a tumor harboring a codon 12, 13, or 61 NRAS-mutation.
recruitment Details
Subprotocol Z1A was activated on May 31, 2016. A total of 114 patients were assigned to this arm after screening, all from screening cohort. Of the 114 patients, 53 patients were enrolled to arm Z1A in the period from May 31, 2016 and June 7, 2018.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice